Navigation Links
Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany

Dr. Mielke Continues his Collaboration With Kiadis Pharma on ATIR(TM)

AMSTERDAM, May 29 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR(TM) with Dr. Stephan Mielke and Professor Dr. Hermann Einsele from the Allogeneic Stem Cell Transplant Center, Division of Hematology and Oncology, Department of Internal Medicine II at the Julius-Maximilians University of Wurzburg, Germany. Principal investigator of this collaboration will be Dr. Mielke.

Previously, Dr. Mielke initiated the ongoing phase II clinical study for ATIR(TM) as principal investigator at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, together with Dr. John Barrett, Chief of the Allogeneic Stem Cell Transplant Section at the Hematology Branch. The investigators selected ATIR(TM) for a clinical study after a pre-clinical research program and have published the pre-clinical data showing promising results with Kiadis Pharma's ATIR(TM) in eliminating alloreactive T-cells from donor grafts (Mielke et al. Blood 2008). Dr. Mielke and colleagues additionally developed a reliable large scale manufacturing protocol with a "GMP-like" semi-closed system for cell processing with ATIR(TM).

"We are extremely pleased with this collaboration which shows the interest of leading transplantation physicians to continue working with our lead product ATIR(TM) as well as to participate in setting up our next clinical study in Europe," says Dr. Manja Bouman, CEO of Kiadis Pharma.

According to Dr. Mielke selective allodepletion with ATIR(TM) carries significant potential for improving the outcome of mismatched (haploidentical ) transplants by allowing early immune reconstitution with less severe or no acute Graft versus Host Disease (GvHD). Therefore, Dr. Mielke and his team and Kiadis Pharma are planning to initiate a clinical phase III study for mismatched (haploidentical) transplantations in blood cancer patients at the Julius-Maximilians University of Wurzburg.

About ATIR(TM)

ATIR(TM) is designed to prevent life-threatening acute GvHD by eliminating the immune cells from the donor graft that otherwise attack the patient's body. Useful donor immune cells that can fight infections and remaining tumor cells are, however, spared, allowing rapid and safe donor immune reconstitution post transplantation. Acute GvHD is a major complication of allogeneic bone marrow transplantations. By preventing the occurrence of acute GvHD, ATIR(TM) enables the use of a mismatched donor and consequently addresses a significant limitation in bone marrow transplantations, which is the timely availability of a donor. Moreover, it could improve the general outcome of bone marrow transplants.

About Kiadis Pharma

Kiadis Pharma is an oncology company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three products in clinical development that offer novel treatment options for terminally ill blood cancer patients and address high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
(Date:11/30/2015)... 2015 North America was ... grow at a CAGR of 7.6% from 2015 to 2020. ... 135.6 million in 2014, and is expected to grow at a ... to the new Market Research Report "North America Cardiac Output Monitoring ... (Hospitals, ambulatory care, others) - Analysis And Forecast To 2020", the ...
(Date:11/30/2015)... --> --> ... by Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application ... Geography - Global Forecast to 2020", published by MarketsandMarkets, is ... CAGR of 5.2% during the forecast period from 2015 to ... 62 Figures spread through 167 P ages and in-depth ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Foundation (Meso Foundation) released information for caregivers and held two webinars on topics ... available on demand free of charge at . , With a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... vehicle experience this summer, ushering in a new era of publicly accessible automated ... electric shuttle, will continue to offer guests an up-close look at the shuttle ...
(Date:11/30/2015)... ... November 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill ... fundraising event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and ... is also located in Battle Creek, joined in for this campaign that sought to ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the week of ... raise funds for its research, education, support, and advocacy efforts. The campaign is ... , The Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds ...
Breaking Medicine News(10 mins):